Covenant Asset Management Portfolio holdings
Top Buys
| 1 |
iShares 0-5 Year TIPS Bond ETF
STIP
|
+$820K |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$302K |
| 3 |
NVIDIA
NVDA
|
+$229K |
| 4 |
Incyte
INCY
|
+$228K |
| 5 |
Air Products & Chemicals
APD
|
+$213K |
Top Sells
| 1 |
Palo Alto Networks
PANW
|
+$205K |
| 2 |
Intel
INTC
|
+$203K |
| 3 |
Biogen
BIIB
|
+$172K |
| 4 |
CELG
Celgene Corp
CELG
|
+$101K |
| 5 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$99K |
Sector Composition
| 1 | Healthcare | 16.97% |
| 2 | Technology | 16.06% |
| 3 | Financials | 12.39% |
| 4 | Communication Services | 10.4% |
| 5 | Industrials | 8.72% |
Similar funds
Covenant Asset Management's Q2 2017 Portfolio in Review
As of Q2 2017, Covenant Asset Management held 137 positions worth $156M, up 5.4% from $148M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Covenant Asset Management deployed $6.36M of net new capital in Q2 2017, opening 7 new positions and adding to 61 existing holdings. Its largest new stake was iShares 0-5 Year TIPS Bond ETF: 8,126 shares worth $816K.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, up from 17% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Palo Alto Networks, an estimated $205K trimmed.
- Covenant Asset Management's largest Q2 2017 buy was iShares 0-5 Year TIPS Bond ETF: 8,126 shares worth $816K.
- Covenant Asset Management added most to Alexion Pharmaceuticals in Q2 2017, an estimated $302K increase.
- Covenant Asset Management's biggest Q2 2017 reduction was Palo Alto Networks, cutting an estimated $205K.
- Covenant Asset Management fully exited Intel in Q2 2017, selling an estimated $203K.
- Covenant Asset Management's ten largest holdings make up 24% of its $156M portfolio in Q2 2017.
- Covenant Asset Management opened 7 new positions and closed 1 in Q2 2017.
- Covenant Asset Management's portfolio value rose 5.4% quarter-over-quarter to $156M.
Based on Covenant Asset Management's 13F filing for Q2 2017, filed 11 Jul 2017.